health
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Dad says he went permanently blind
New York Post
I'm a woman in my 20s and I'm not have the sex I want. I know what's holding me back.
Slate
Millions of cancer cases are linked to 5 common infections: study
New York Post
45-year-old man died after ER sent him home without antibiotics, lawsuit says
OregonLive.com
19 Harmless Symptoms That Are Major Medical Red Flags
BuzzFeed